Therefore, several studies have documented the efficacy of capivasertib in managing hormone receptor-positive breast cancer and tumors harboring AKT1 mutations, highlighting its potential as a pivotal component in targeted cancer therapy. The gene discussed is AKT1; the disease is cancer.